Delivery Order SPE2DB20D1100-SPE2DB25FD4P3
- Not listed
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. This firm fixed-price, competitively awarded delivery order was issued on September 3, 2025, with an ultimate completion date of September 4, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $2,234.96 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen (0.5ml), a GLP-1 receptor agonist medication used for weight management. The contract is a firm fixed-price delivery order with no set-aside designation, awarded on August 26, 2025, with an ultimate completion date of August 27, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,906.45 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injection on October 23, 2025, with an ultimate completion date of October 24, 2025. This non-competitive, firm fixed-price delivery order represents a single shipment of the GLP-1 receptor agonist medication used for weight management. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, leveraging the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,575.48 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. The contract was awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, and represents a competitively awarded, firm fixed-price transaction with no set-aside designation. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $1,928.55 to AmerisourceBergen Drug Corp for ZEPBOUND 2.5 MG/0.5 ML Pen 0.5ML, a GLP-1 receptor agonist medication used for weight management. The contract, awarded on August 28, 2025, with an ultimate completion date of August 29, 2025, was competitively awarded without set-aside designation and carries firm fixed pricing. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $1,476.56 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen (0.5 mL), a GLP-1 receptor agonist medication used for weight management. The award was issued on December 15, 2025, with an ultimate completion date of December 16, 2025, under firm fixed price terms with no set-aside designation. The contract represents a competitive award to the prime contractor, with performance of the delivery occurring at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,906.47 for Zepbound 2.5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under AmerisourceBergen...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens, a GLP-1 receptor agonist medication used for weight management. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,050.40 and an ultimate completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens, a GLP-1 receptor agonist medication used for weight management. This firm fixed price delivery order, valued at $1,041.62, represents a non-competitive set-aside award under DLA's pharmaceutical supply chain. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of...
- The Defense Logistics Agency awarded a $11,086.64 delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors (0.5 mL), a GLP-1 receptor agonist medication used for weight management. This firm fixed price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD4P3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,213.05 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. The contract was awarded on July 16, 2025, with an ultimate completion date of July 17, 2025, and utilizes firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare systems worldwide, including the Defense Health Agency and U.S. Coast Guard. The award reflects the company's ongoing role as a critical vendor in the federal medical procurement supply chain, demonstrating its capability to meet competitive federal procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 7/16/25 |